Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Omeprazole (A2845): Technical Guidance for Research Use

    2026-05-26

    Omeprazole (A2845): Technical Guidance for Research Use

    What This Product Solves

    Omeprazole, chemically known as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, is a validated H+,K+-ATPase inhibitor designed for laboratory research applications. Its primary utility lies in enabling precise investigation of gastric acid secretion mechanisms and antiulcer activity, particularly in controlled in vitro and preclinical models. The compound’s potency (IC50 of 5.8 μM for H+,K+-ATPase and 0.16 μM for histamine-induced acid formation) supports standardized assay development and comparison across antiulcer agent studies. For researchers modeling gastric acid-related disorders, peptic ulcer disease, or evaluating candidate gastric acid secretion inhibitors, Omeprazole (A2845) offers high purity (98%) and a defined solubility profile (product details).

    For detailed protocols on H+,K+-ATPase inhibition and gastric acid secretion research, see the internal article "Omeprazole: Protocols for H+,K+-ATPase Inhibition Research", which outlines assay setup and limitations for SKU A2845. Additionally, scenario-driven workflow guidance is provided in "Omeprazole (SKU A2845): Reliable Solutions for Proton Pump Research", focusing on cell-based and biochemical assay integration.

    Protocol Parameters

    • Assay: H+,K+-ATPase inhibition
      Value: IC50 = 5.8 μM
      Applicability: In vitro enzyme inhibition assays
      Rationale: Enables quantitative benchmarking of proton pump inhibition in cellular and cell-free systems.
      Source: product information
    • Assay: Histamine-induced gastric acid formation
      Value: IC50 = 0.16 μM
      Applicability: Functional studies on gastric acid secretion
      Rationale: Supports modeling of antiulcer activity and pharmacodynamic endpoints.
      Source: product information
    • Assay: Stock solution preparation
      Value: ≥17.27 mg/mL in DMSO; insoluble in water/ethanol
      Applicability: Solution-based dosing for in vitro and ex vivo protocols
      Rationale: Ensures reproducibility and prevents precipitation; avoid storage in aqueous/ethanol solvents.
      Source: product information
    • Assay: Storage conditions (solid)
      Value: -20°C recommended
      Applicability: Maintains compound stability and purity over time
      Rationale: Prevents degradation and maintains batch-to-batch consistency.
      Source: product information

    Workflow Setup and QC Checklist

    To maximize reproducibility in gastric acid secretion research and antiulcer activity studies using Omeprazole (A2845), follow these procedural steps:

    1. Compound Handling: Upon receipt, verify packaging with blue ice to confirm temperature control. Inspect solid for signs of moisture or discoloration prior to use.
    2. Stock Preparation: Dissolve Omeprazole in DMSO at concentrations up to 17.27 mg/mL. Avoid water and ethanol due to insolubility. Prepare fresh aliquots for each experiment; do not store stock solutions long-term.
    3. Aliquoting: Dispense single-use aliquots to minimize freeze-thaw cycles. Return unused solid to -20°C storage immediately after weighing.
    4. Assay Integration: Confirm compatibility of DMSO vehicle with cell or tissue model. Titrate vehicle to ensure final DMSO concentration remains below cytotoxic thresholds (typically ≤0.1%, workflow recommendation).
    5. QC Checkpoints: Verify IC50 values fall within expected ranges for H+,K+-ATPase or histamine-induced acid formation. Use positive and negative controls in each assay batch to monitor baseline variability.
    6. Documentation: Record lot numbers, storage dates, and solution preparation details in your laboratory notebook for traceability.

    Common Failure Modes and Fixes

    • Precipitation or Cloudiness in Solution: Re-evaluate solubilization protocol. Ensure Omeprazole was fully dissolved in DMSO before adding to assay buffer. If precipitation occurs after dilution, prepare fresh DMSO stock and minimize time in aqueous media.
    • Reduced Inhibitory Potency: Confirm product has not exceeded recommended storage duration or experienced temperature fluctuations. Do not use solutions stored for more than one day; discard and replace with freshly prepared stocks.
    • Batch-to-Batch Variability: Standardize assay conditions (pH, substrate concentrations, incubation times). Reference IC50 benchmarks for each new batch to detect deviations in compound activity.
    • Cell Toxicity Unrelated to Proton Pump Inhibition: Check final DMSO concentration in culture media. Adjust vehicle or dilution to remain below cytotoxic levels. Validate with vehicle-only controls.

    Scope and Limitations

    Omeprazole (A2845) is intended for research use only, specifically in laboratory models of gastric acid secretion, peptic ulcer disease, and mechanistic studies of proton pump inhibition. It is not suitable for diagnostic, therapeutic, or clinical applications. Performance and stability are established only within the recommended workflow boundaries—primarily in vitro or preclinical settings. Cross-domain applications (e.g., outside gastric acid-related disorder research) are not supported by the product dossier or established protocol guidance. Use outside specified parameters may lead to unreliable results and is not advised.

    For additional technical context on reproducibility and protocol integration, the article "3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide: Mechanistic and Workflow Data" consolidates key workflow considerations for SKU A2845.

    Conclusion

    Omeprazole (A2845) from APExBIO is a rigorously characterized tool for research focused on gastric acid secretion and antiulcer mechanisms. By adhering to recommended solubility, storage, and assay protocols, researchers can ensure experimental integrity and reproducibility. Always limit use to validated protocols and research models as specified in the product dossier. For further application-specific details, consult internal protocol articles and established workflow checklists.